Where Will Summit Therapeutics Be in 3 Years?

Believe it or not, it's entirely possible to build out a successful biopharma without actually doing much (or any) work in the laboratory. And, at least for now, that's exactly what Summit Therapeutics (NASDAQ: SMMT) is angling to do. Thanks to its collaboration with a highly capable company abroad, this biotech may soon demonstrate the powerful financial performance that's possible using an asset-light business model.With that frame in mind, let's sketch out its most probable trajectory over the next three years for Summit Therapeutics as there are guaranteed to be critical periods for this biotech.Summit's focus over the next three years or so will be to wrap up its two late-stage clinical programs for treating certain patient populations with advanced or metastatic non-small cell lung cancer (NSCLC) in combination with other treatments like chemotherapy and attempt to get regulators on board with commercializing them.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool